This is a Phase I, randomised, single-blind, placebo-controlled study. The healthy Japanese participants will receive randomly (3:1) either AZD7503 or placebo subcutaneously.
The study will comprise of:
* A screening period of 28 days.
* Randomization on Day 1.
* A 9-week Treatment Period. Dose 1 will be administered on Day 1. Dose 2 will be administered at the study site on Day 29. Dose 3 will be administered on Day 57.
* A follow-up period of 10 week after last dose of study intervention.
* The total duration of the study will be 23 weeks
